{"title":"Prospective Head-to-Head Comparison of Fibroblast Imaging with [68Ga]Ga-FAPI-46 PET/CT and [18F]FDG PET/CT in Unclear Hepatic Lesions.","authors":"Susanne Stanzel,Tina Nazerani-Zemann,Friedrich Weitzer,Elisabeth Plhak,Ariane Aigelsreiter,Thomas Kuenzer,Herbert Kvaternik,Jasminka Igrec,Jan Bucerius","doi":"10.2967/jnumed.125.271597","DOIUrl":null,"url":null,"abstract":"This study aimed to compare the performance of 68Ga-labeled fibroblast activation protein inhibitor 46 ([68Ga]Ga-FAPI-46) PET/CT and [18F]FDG PET/CT in characterizing unclear hepatic lesions. Methods: We prospectively evaluated 59 patients with suspected intrahepatic lesions. Tumor radiologic features, pathology, or follow-up examinations were assessed as reference methods in correlation with PET scans. On [68Ga]Ga-FAPI-46 PET/CT, additional abdominal dynamic imaging was performed. We measured the SUV and calculated tumor-to-liver background ratios for both scans. Fibroblast activation protein expression was assessed by immunohistochemistry in samples obtained from 16 patients with hepatocellular carcinoma/cholangiocarcinoma, intrahepatic metastases (IMs) from extrahepatic malignancies, or benign lesions. Results: Primary hepatobiliary tumors (PHBTs), including 76 hepatocellular carcinomas in 22 patients, 24 cholangiocarcinomas in 5 patients, 136 IMs in 16 patients, and 55 benign lesions in 16 patients, were determined by histology (n = 162) and radiologic examinations (n = 129). On the basis of visual analysis, 44 patients showed elevated [68Ga]Ga-FAPI-46 uptake (sensitivity, 100%; specificity, 94%), whereas 32 patients showed [18F]FDG-avid lesions (sensitivity, 70%; specificity, 88%). Sensitivity was significantly higher in [68Ga]Ga-FAPI-46 PET/CT than in [18F]FDG PET/CT (P < 0.001). Fifty (90.9%) benign liver lesions in 14 patients (87.5%) showed negligible uptake on both PET scans, and 1 (1.8%) benign liver lesion in 1 patient showed increased [18F]FDG uptake alone. [68Ga]Ga-FAPI-46 PET/CT revealed 10 extrahepatic primary tumors, versus 3 in [18F]FDG PET/CT. SUVmax for PHBTs, maximum tumor-to-background ratio for PHBTs, and mean tumor-to-background ratio for PHBTs were significantly higher on [68Ga]Ga-FAPI-46 PET/CT than on [18F]FDG PET/CT (all P < 0.05). Conclusion: [68Ga]Ga-FAPI-46 PET/CT is superior to [18F]FDG PET/CT in characterizing unclear hepatic lesions.","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"13 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Nuclear Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2967/jnumed.125.271597","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
This study aimed to compare the performance of 68Ga-labeled fibroblast activation protein inhibitor 46 ([68Ga]Ga-FAPI-46) PET/CT and [18F]FDG PET/CT in characterizing unclear hepatic lesions. Methods: We prospectively evaluated 59 patients with suspected intrahepatic lesions. Tumor radiologic features, pathology, or follow-up examinations were assessed as reference methods in correlation with PET scans. On [68Ga]Ga-FAPI-46 PET/CT, additional abdominal dynamic imaging was performed. We measured the SUV and calculated tumor-to-liver background ratios for both scans. Fibroblast activation protein expression was assessed by immunohistochemistry in samples obtained from 16 patients with hepatocellular carcinoma/cholangiocarcinoma, intrahepatic metastases (IMs) from extrahepatic malignancies, or benign lesions. Results: Primary hepatobiliary tumors (PHBTs), including 76 hepatocellular carcinomas in 22 patients, 24 cholangiocarcinomas in 5 patients, 136 IMs in 16 patients, and 55 benign lesions in 16 patients, were determined by histology (n = 162) and radiologic examinations (n = 129). On the basis of visual analysis, 44 patients showed elevated [68Ga]Ga-FAPI-46 uptake (sensitivity, 100%; specificity, 94%), whereas 32 patients showed [18F]FDG-avid lesions (sensitivity, 70%; specificity, 88%). Sensitivity was significantly higher in [68Ga]Ga-FAPI-46 PET/CT than in [18F]FDG PET/CT (P < 0.001). Fifty (90.9%) benign liver lesions in 14 patients (87.5%) showed negligible uptake on both PET scans, and 1 (1.8%) benign liver lesion in 1 patient showed increased [18F]FDG uptake alone. [68Ga]Ga-FAPI-46 PET/CT revealed 10 extrahepatic primary tumors, versus 3 in [18F]FDG PET/CT. SUVmax for PHBTs, maximum tumor-to-background ratio for PHBTs, and mean tumor-to-background ratio for PHBTs were significantly higher on [68Ga]Ga-FAPI-46 PET/CT than on [18F]FDG PET/CT (all P < 0.05). Conclusion: [68Ga]Ga-FAPI-46 PET/CT is superior to [18F]FDG PET/CT in characterizing unclear hepatic lesions.